辅助放射治疗和患有恶性小瘤的患者的存活率:基于人口的回顾性研究
Gongyin Zhang1, Liqun Yang2, Foyan Xu3
1Section for Gastrointestinal Surgery, Department of General Surgery, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, 610031, China.
Breast cancer (Tokyo, Japan)
|November 22, 2025
概括
辅助放射治疗 (RT) 并没有改善恶性乳腺瘤 (MPTB) 的存活率. 这项研究发现,RT对生存没有益处,即使是在高风险的MPTB患者中也是如此.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 辐射瘤学 辐射瘤学
背景情况:
- 恶性乳腺瘤 (MPTB) 是罕见的,可以有侵略性行为.
- 辅助放射治疗 (RT) 在MPTB管理中的作用仍然存在争议.
- 评估MPTB中RT的生存益处对于治疗优化至关重要.
研究的目的:
- 为了确定辅助放射治疗 (RT) 是否改善了被诊断为患有恶性乳腺Phyllodes瘤 (MPTB) 的患者的生存结果.
主要方法:
- 一项回顾性队列研究利用了来自SEER数据库的1899名成年MPTB患者的数据.
- 倾向性得分匹配 (PSM) 用于平衡RT和非RT组之间的基线特征.
- 卡普兰-梅尔分析和多变量考克斯回归模型评估了乳腺癌特定存活率 (BCSS) 和整体存活率 (OS).
主要成果:
- 辅助RT与MPTB患者的BCSS或OS改善无关,即使在PSM之后.
- 多因素分析显示,在MPTB中RT没有显著的生存益处 (HR>0.9).
- 根据瘤等级,阶段或手术方法进行的子组分析没有确定从RT中受益的患者群体.
结论:
- 辅助RT与恶性乳腺瘤 (MPTB) 的长期存活率的改善无关.
- 这一发现甚至适用于具有高风险MPTB特征的患者.
- 需要进一步的前性研究来确定RT在MPTB中的治疗价值.
更多相关视频
相关概念视频
Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


